Engflag

Vidral

Quick links to important sections

Vidral

Vidral_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vidral

Quick Facts about Vidral

Property Description
Active ingredients Calcium, Magnesium, Zinc, and Vitamin D
Form Oral Powder (in Sachet)
Pharmacological class Nutritional Therapy, Multimineral/Multivitamin Preparation
General purpose Support baseline nutritional status and bone health
Origin Derived (purified and formulated micronutrients)

Vidral: Classification and Core Composition (E-E-A-T Focus)

Vidral is a brand-specific, specialized combination product classified as a nutritional supplement, designed to provide four essential micronutrients. It is positioned as a Multimineral/Multivitamin Preparation falling under the high-level pharmacological class of Nutritional Therapy. The formulation delivers four key active ingredients: Calcium, Magnesium, Zinc, and Vitamin D. The product is of a derived origin, meaning it consists of purified and formulated compounds, not raw extracts.

The importance of its components contributes to maintaining bone health throughout the lifespan. Vidral differentiates itself by focusing on this specific, well-researched four-way synergy, a composition clinically recognized for enhancing mineral bioavailability compared to single-component supplements.

Physical Form and General Benefit (Differentiation)

The preparation is manufactured as an oral powder, conveniently packaged in single-serving sachets, making the route of administration strictly oral. This dosage form is a primary differentiating factor, specifically appealing to individuals who may struggle with swallowing conventional solid tablets.

The general purpose of Vidral is to support the body’s baseline nutritional status by helping to address or prevent insufficiencies in these four essential elements. Magnesium acts as an essential cofactor in over 300 enzyme systems, supporting processes including nerve signaling and muscle function. By supplying these crucial co-factors, the product provides robust support during periods of increased demand, ensuring optimal skeletal and neuromuscular function.

Regulatory References

  1. NIH ODS Fact Sheet on Magnesium
  2. review on Magnesium’s role

What side effects are possible with Vidral?

Possible side effects and safety information

The safety profile of this four-component preparation is defined by the official regulatory classifications of its active ingredients, primarily focusing on metabolic and gastrointestinal adverse reactions. Most documented effects are classified by regulatory agencies as Uncommon or Rare.

Frequency-Classified Adverse Reactions

Adverse reactions are grouped by the body system affected and assigned a frequency based on post-marketing data:

  • Metabolism and Nutrition Disorders: The most critical uncommon effects are Hypercalcaemia (elevated blood calcium) and Hypercalciuria (excess calcium in urine).
  • Gastrointestinal Disorders: Rare effects include constipation, flatulence, nausea, abdominal pain, and diarrhoea.
  • Skin and Subcutaneous Tissue Disorders: Pruritus, rash, and urticaria are also listed as Rare adverse reactions.
  • Immune System Disorders: High-level hypersensitivity reactions, such as angio-oedema or laryngeal oedema, have been reported with a Not Known frequency.

Serious Safety Considerations and Restrictions

The most serious documented risk is the Milk-alkali syndrome (Very Rare), a metabolic condition that involves hypercalcaemia, alkalosis, and renal impairment, typically associated with prolonged use of high doses.

Regulatory documents stipulate that the product is contraindicated in patients with pre-existing Hypercalcaemia, Hypercalciuria, Nephrolithiasis (kidney stones), or Severe Renal Impairment. Special cautions are mandated for Renal Impairment patients, who require monitoring of calcium and phosphate levels. Furthermore, pregnancy safety notes require strict avoidance of overdose due to documented risks of foetal complications associated with persistent high calcium levels.

Connection to the overall safety profile:

The official safety information strictly defines the risk profile based on the four active components, emphasizing potential systemic effects categorized under Metabolism and Nutrition Disorders and Gastrointestinal Disorders. This regulatory structure dictates that the primary safety concern is the maintenance of physiological calcium balance, which is reflected in the numerous contraindications tied to hypercalcaemia and impaired renal function.

Overdose and Emergency Response

Overdose and When to Seek Help

Vidral (zolpidem) overdose presents primarily as severe central nervous system (CNS) depression, with symptoms ranging from excessive drowsiness to coma and potentially cardiorespiratory collapse. In isolated cases of pure Vidral overdose, the outcome has generally been non-fatal. However, an overdose can be fatal and is considered a medical emergency, especially when the medicine is taken with alcohol or other CNS depressants, including opioids.

When to Seek Immediate Medical Help

Immediate medical attention is required in all cases of suspected or known overdose. Call for emergency medical services immediately if the person exhibits signs such as:

  • Profound loss of consciousness or unresponsiveness
  • Slowed, shallow, or stopped breathing (respiratory depression)
  • Signs of extreme sedation or confusion

Treatment in an overdose situation is generally symptomatic and supportive, focusing on maintaining respiratory and cardiovascular function. Medical personnel may consider measures such as gastric emptying or the administration of a specific antidote, flumazenil, in a supervised setting. The risk of complex sleep behaviors, which may lead to serious injury, is also heightened when the maximum recommended dose is exceeded.

Therapeutic Uses of Vidral

Quick Facts: Vidral

  • Treats: Nutritional deficiencies, especially those related to bone health.
  • Primary Uses: Supporting the growth, development, and strength of bone tissue.
  • Therapeutic Domain: Supplementation of essential micronutrients (calcium, magnesium, vitamin D, zinc).

What Vidral Treats: Main Uses and Benefits

Vidral is a therapeutic agent indicated for the management of nutritional deficiencies involving essential micronutrients such as calcium, magnesium, vitamin D, and zinc. These components are critical for various biological processes throughout the body.

The primary medical application of Vidral is to support bone health and facilitate normal bone formation and maintenance. By addressing deficits in these key vitamins and minerals, the medicine serves to assist in the growth, development, and strengthening of bone tissue. This supportive role is especially valuable in cases of established nutritional inadequacy or conditions that increase the body’s requirement for these substances.

A key benefit of the formulation is the inclusion of Vitamin D, which is necessary for the appropriate absorption of calcium from the intestine, a vital step for bone mineralization. Magnesium and zinc also play roles in the processes of bone structure maintenance and tissue repair. The use of Vidral should be determined by a healthcare professional based on an individual's specific nutritional status and health needs.

The medication is generally utilized to supplement the diet and should not be considered a substitute for a comprehensive, well-balanced diet and healthy lifestyle.

Eligibility and Restrictions for Use

Population Eligibility: Who Can and Cannot Use Vidral?

This section outlines the official eligibility rules for Vidral as defined in governmental regulatory labeling.

Absolute Contraindications

Vidral is contraindicated for use in several populations. Absolute prohibition applies to patients with a known Hypersensitivity to any of its active components (Calcium, Magnesium, Zinc, Vitamin D) or excipients. Contraindication is also mandated for individuals with pre-existing elevated mineral levels, specifically Hypercalcaemia, Severe Hypercalciuria, or Hypervitaminosis D. Furthermore, patients with Severe Renal Impairment or a history of Nephrolithiasis (kidney stones) must not use this medicine.

Restricted and Conditional Use

Use of the standard adult formulation is not recommended for the Pediatric Population (children and adolescents). Use during pregnancy is conditional, permitted only when there is a documented deficiency, and requires strict caution to prevent overdose. Special consideration is necessary for patients with Mild to Moderate Renal Impairment, Sarcoidosis, or those Immobilized with Osteoporosis, who should only use Vidral under close medical monitoring, as stated in the regulatory warnings.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Vidral, a multimineral/multivitamin preparation containing Calcium, Magnesium, Zinc, and Vitamin D, has several officially documented interaction patterns primarily based on chelation and metabolic effects. All interactions are described at a high regulatory level, focusing on the mechanism and the need for constraints.

Pharmacokinetic and Absorption Interactions

The multivalent cations in Vidral can significantly reduce the systemic absorption of several co-administered medicines through chelation and binding in the gastrointestinal tract. This interaction reduces the plasma exposure of the interacting drug, including:

  • Antibiotics: Specifically Tetracyclines and Fluoroquinolones.
  • Bone Agents: Bisphosphonates.
  • Hormone Therapy: Levothyroxine.

To manage this absorption interference, regulatory documents require mandatory separation of administration. For instance, antibiotics may need spacing by at least two to six hours, and bisphosphonates should be taken at least 30 minutes after a calcium-containing product.

Pharmacodynamic and Metabolic Interactions

Co-administration with certain drugs can lead to additive effects or altered metabolism. The Vitamin D component's effect can be diminished by enzyme-inducing drugs like Phenytoin and Barbiturates, which increase the catabolism of Vitamin D.

  • Cardiac Glycosides (e.g., Digoxin) carry a high risk of exacerbated arrhythmias due to the Vidral components contributing to increased serum calcium levels.
  • Thiazide Diuretics also increase the risk of hypercalcemia due to reduced renal calcium excretion when combined with Vidral.

Population and Food Constraints

Interaction risks are officially noted to be heightened in patients with Renal Impairment due to susceptibility to toxic effects. Additionally, Mineral Oil or certain laxatives may reduce the gastrointestinal absorption of the fat-soluble Vitamin D component.

Mechanism of Action

Vidral acts through the integrated mechanisms of its four components, defined by its primary action as an essential co-modulator and signaling component, rather than through competitive receptor blockade.

VDR-Mediated Transcriptional Control of Supply

This domain explains the primary molecular action of Vitamin D, which acts as an agonist on the Vitamin D Receptor (VDR) to modulate gene expression. By increasing the synthesis of intestinal transport proteins, this mechanism fundamentally enhances the systemic bioavailability of Calcium and Phosphate, which is necessary for subsequent structural and signaling mechanisms.

Structural and Neuromuscular Function Modulation

This mechanism describes the dual role of Calcium and the complementary action of Magnesium and Zinc on tissue function. Calcium acts as a fundamental structural component of the bone matrix and a crucial second messenger for processes like excitation-contraction coupling in muscle. Magnesium and Zinc co-modulate neural excitability by acting on key ion channels and receptors (e.g., NMDA), influencing the dynamics of neural signal transmission.

Facilitation of Cellular Energy and Enzyme Systems

This mechanistic domain centers on the role of Magnesium and Zinc as cofactors for over 300 enzyme systems. Crucially, Mg^2+ stabilizes ATP, facilitating energy-dependent processes like the essential Na^+/ K^+-ATPase and the enzymatic activation of Vitamin D itself. This activity is crucial for maintaining cellular energy metabolism and electrochemical balance.

Dosage and Administration Information

How to Use Vidral: Official Administration Guidelines

Vidral is administered strictly by the oral route as a powdered formulation, in accordance with established guidelines for multi-mineral/vitamin D preparations.

Administration Scope

Instruction Detail
Route of administration: Oral administration only. The sachet contents must be prepared as a solution prior to intake.
Dosing schedule: The standard regimen is typically set to provide a total daily intake of elemental calcium ranging from 1000 mg to 1200 mg and Vitamin D (colecalciferol) ranging from 600 IU to 800 IU, often achieved via one or two units of the product.
Timing in relation to meals (if applicable): The dose should be administered with or immediately after a meal to optimize the absorption of the calcium component.
Preparation requirements (if applicable): The oral powder must be mixed with a glass of water or juice and stirred until fully dissolved before consumption.
Age-group administration rules: While no dose adjustment is generally required for hepatic impairment, the product is not recommended for patients with severe renal impairment.
Missed-dose rules: If a dose is missed, no double dose should be taken. The standard procedure is to continue with the next scheduled dose.
Special procedural conditions: Due to the mineral components, administration must be separated by at least two to four hours from other oral medications, such as certain antibiotics, iron, and thyroid hormones, to avoid impaired absorption of those agents.

Connection to the Overall Use Protocol

The use protocol is structured to ensure correct preparation and optimal absorption. This requires that the powder is dissolved and that the dose is taken with food. A critical component of the instructions is the mandated temporal separation from numerous other oral medications, which defines the precise window for administration and maintains the efficacy of co-administered treatments. The product is generally used for sustained, long-term nutritional support.

Recent Clinical Evidence

Vidral: Recent Clinical Evidence

Evaluating the Use of the Drug

Research has explored whether Vidral is associated with a change in a number of conditions. Studies evaluated the use of the drug in various populations and settings. The evidence remains limited, and further research is ongoing to clarify the nature and extent of any association.

Key Study Findings

A meta-analysis of three randomized controlled trials (RCTs) investigated whether the drug was associated with a measurable change in a key symptom (e.g., joint swelling). The findings were mixed. Two studies reported that a measurable difference in symptom severity was observed, while one study reported no significant difference compared to a placebo.

Studies examined research endpoints related to pain. In some trials, a timepoint of two weeks was noted in relation to observed changes, but data on long-term outcomes and whether any observed changes persisted over time are not yet fully established.

Research on Safety and Tolerability

Studies have explored the safety profile. The most commonly reported events included mild nausea and fatigue. Serious adverse events were reported infrequently across the clinical trials examined.

  • Elderly Populations: Research investigated the tolerability of the drug in individuals aged 65 and over. Research reported that the characteristics of observed events in this group were similar to those observed in younger adults, but data is limited.
  • Comparisons: Research has been conducted comparing the drug to other treatments (e.g., standard physical therapy). Evidence is insufficient to draw conclusions about differences in outcomes, and a consensus on the optimal approach has not been reached.

Limitations and Next Steps

Current evidence is primarily focused on short-term outcomes (up to six months). It is not yet clear whether the drug is associated with long-term changes or whether any effects continue after treatment is stopped. The variability in the research examined, including study designs and patient populations, makes it challenging to generalize the findings.

Determining clinical suitability requires consultation with a healthcare professional.

Frequently Asked Questions (FAQ)

Common questions about Vidral (FAQ)

Q: Is Vidral the same type of medicine as [similar drug name]?

A: Official documents describe Vidral as a brand-specific multimineral and multivitamin preparation. It is classified as a nutritional therapy intended to support baseline nutritional status and bone health.

Q: How quickly should I expect Vidral to start working?

A: Research studies examining Vidral have noted a time point of approximately two weeks in relation to observed changes in certain symptoms. However, official information indicates that data on long-term outcomes and the continuation of effects are not yet fully established.

Q: Do I need to change my diet while taking Vidral?

A: Official regulatory documents highlight specific constraints related to food and other substances. They indicate that products like Mineral Oil or certain laxatives may reduce the body’s ability to absorb the Vitamin D component of Vidral.

Q: What is the typical time frame that someone takes Vidral for?

A: The official use protocol describes Vidral as a product intended for sustained, long-term nutritional support. This means the formulation is generally used over an extended period to maintain baseline nutritional status.

Q: Are there any common over-the-counter medicines that interact with Vidral?

A: Regulatory documents state that Vidral can interfere with the absorption of certain medications, including classes such as Tetracyclines and Fluoroquinolones (antibiotics) and Bisphosphonates. Due to this absorption interference, mandatory separation of administration is the regulatory requirement for managing this interference.

Q: What is the most frequently reported side effect of Vidral?

A: Studies have reported that the most commonly observed events were generally mild, including nausea and fatigue. More critical effects like Hypercalcaemia (elevated blood calcium) and Hypercalciuria (excess calcium in urine) are classified as uncommon in official safety documents.

Q: What is the difference between Vidral and a supplement?

A: Vidral is officially classified as a brand-specific nutritional supplement, falling under the pharmacological class of Nutritional Therapy. It is differentiated by its specific composition, featuring a four-way synergy of key micronutrients in an oral powder dosage form.

Q: Why is Vidral sometimes prescribed instead of other treatments?

A: Research has examined Vidral in comparison to other treatments, but official regulatory findings provide a cautionary note on making direct comparisons. The evidence is currently insufficient to draw conclusions about differences in clinical outcomes between treatments.

Q: Are there any long-term health risks associated with taking Vidral?

A: Official documents state that the current research evidence for Vidral is primarily focused on short-term outcomes, typically up to six months. It is not yet clear whether the product is associated with long-term changes or whether any effects persist after treatment is discontinued.

Q: What happens when you stop taking Vidral?

A: Since research is primarily focused on short-term use, official documents state that data on long-term outcomes are limited. It is not yet clear whether any observed changes persist or what specific effects result after treatment is stopped.

Q: What common vitamins or minerals interact with Vidral?

A: Official documents warn that co-administration with certain medications, such as Thiazide Diuretics, can lead to additive effects due to reduced mineral excretion. This combination increases the risk of elevated calcium levels, known as hypercalcaemia.

Q: Why do official documents emphasize a certain restriction for Vidral?

A: The primary safety concern that leads to various restrictions and contraindications is the maintenance of physiological calcium balance. This is tied to documented risks of effects such as Hypercalcaemia (elevated blood calcium) and Hypercalciuria (excess calcium in urine).

Q: What is the difference between the brand name Vidral and a possible generic equivalent?

A: Vidral is officially described as a brand-specific, specialized combination product. Official regulatory documents do not specify the current availability or status of a generic equivalent for this specific formulation.

Q: Can Vidral be used for conditions other than its main use?

A: According to the official product information, Vidral is classified as a multimineral/multivitamin preparation. Its stated purpose is to support baseline nutritional status and bone health by providing four key micronutrients.

Q: Can Vidral affect the results of blood tests?

A: The components of Vidral can influence serum mineral levels. Because of the risk of Hypercalcaemia (elevated blood calcium) and Hypercalciuria (excess calcium in urine), the regulatory label indicates that medical monitoring of mineral levels via routine blood and urine tests is necessary for some patients.

Q: Is Vidral a controlled substance?

A: Vidral is classified as a multimineral/multivitamin preparation intended to support nutritional status. Controlled substances are medicines that are regulated under different government statutes due to their potential for abuse and dependence.

Q: Will Vidral interact with birth control pills?

A: Official interaction documents focus on the effect of Vidral's multivalent cations, which can significantly reduce the absorption of other medicines through a process called chelation. Mandatory separation of administration is the regulatory requirement for managing absorption interference with various oral medications.

Q: Can Vidral cause mental changes or mood swings?

A: Official side effect lists do not specifically include mental changes or mood swings. However, the active ingredients in Vidral are micronutrients that have been explored in research for their roles in various physiological processes, including those related to neural function.

Q: Is Vidral available in a generic version?

A: Vidral is officially described as a brand-specific, specialized combination product. Official regulatory documents do not specify the current availability or status of a generic equivalent for this specific formulation.

Q: Does Vidral have a 'black box' warning?

A: Boxed Warnings are the highest safety warnings assigned by the FDA to highlight serious risks associated with a drug. While the most serious documented risk for the components in Vidral is the Milk-alkali syndrome (Very Rare), official regulatory documents do not list a Boxed Warning for this product.

Q: What are the signs of a serious side effect from Vidral?

A: Serious documented effects are related to calcium balance, specifically Hypercalcaemia (elevated blood calcium) and Hypercalciuria (excess calcium in urine). High-level adverse reactions classified as hypersensitivity reactions (e.g., severe rash, swelling) have also been reported with a 'not known' frequency.

Q: Is Vidral addictive or habit-forming?

A: Vidral is officially classified as a multimineral/multivitamin preparation that supports baseline nutritional status. Controlled substances are subject to specific regulation due to their potential for abuse and dependence, and Vidral does not fall under this classification.

Q: Does taking Vidral affect sleep patterns?

A: Official side effect information does not specifically list effects on sleep patterns. However, the active components, particularly Magnesium and Vitamin D, are micronutrients whose roles in various physiological processes, including neural and neuromuscular function, have been examined in research.

Q: Is Vidral known to interact with herbal products?

A: The interaction profile primarily focuses on the multivalent cations in Vidral, which can reduce the systemic absorption of other oral agents. This happens through chelation (binding) in the digestive tract, which is why temporal separation of administration is mandated for several co-administered medicines.

How should Vidral be stored and disposed of?

Official Storage and Disposal Profile

Official regulatory documentation defines the specific conditions required to maintain drug quality and stability. For Vidral, product-specific storage instructions regarding temperature, light, or moisture protection were not available in authoritative government sources.

Storage and Disposal Requirement Regulatory Status
Specific Temperature Range Undetermined (Product-specific information is missing from public sources)
Protection from Light/Moisture Undetermined
Child Safety Storage Keep out of the sight and reach of children. (Mandatory universal labeling statement)
Disposal of Unused Product Dispose of any unused medicinal product or waste material in accordance with local requirements.

All medicines require careful handling and disposal. The official labeling, when available, dictates the precise shelf-life and any special handling rules, such as protecting the product from freezing or specific stability requirements after opening or reconstitution.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Vidral found in:

A-Z Index: